Mylan Pharmaceuticals Inc., a subsidiary of generic pharma major Mylan Inc. (NYSE:MYL), recently announced that it has received final approval from the U.S. Food & Drug Administration (FDA) for its generic version of Boehringer Ingelheim’s Viramune (nevirapine).
Viramune is approved for HIV-1 infection in combination with antiretroviral (ARV) treatment. According to IMS Health, Viramune generated U.S. revenues of approximately $116.6 million for the 12 months ending March 31, 2012.
Apart … [visit site to read more] or compare Credit Card Rewards and Best Credit Cards
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here